Gaviani Paola, Simonetti Giorgia, Rudà Roberta, Franchino Federica, Lombardi Giuseppe, Possanzini Marco, Squintu Sara, Villani Veronica, Teriaca Mariaausilia, Cavallieri Francesco, Caffo Maria, Salmaggi Andrea, Bianco Andrea, Anghileri Elena, Farinotti Mariangela, Tramacere Irene, Silvani Antonio
Neuro-oncology Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy.
Department of Neuro-Oncology, University of Turin and City of Health and Science University Hospital, Turin, Italy.
Neurol Sci. 2021 Feb;42(2):665-671. doi: 10.1007/s10072-020-04556-6. Epub 2020 Jul 11.
Medulloblastoma (MB) is the most common primary malignant intracranial tumor in childhood, but it is very rare in adults, and for this reason, the optimal treatment has not yet been defined. We designed a multicentric study in order to define relevant outcome measures for future prospective studies.
The project involved 10 Italian centers. The database shared among the centers contains epidemiological, diagnostic (radiological and histological/molecular), therapeutic, recurrence information, and survival data.
A total of 152 patients (102 males and 50 females, median age 32) were included in the study. Twenty-three of 152 patients had a diagnosis of classic medulloblastoma, 52/152 had desmoplastic/extensive nodularity, 2/152 had large-cell anaplastic medulloblastoma, and the remaining had diagnoses not otherwise specified. Almost all patients underwent craniospinal irradiation after surgery; in 85.5% of patients, adjuvant chemotherapy, mainly platinum- and etoposide-based chemotherapy, was performed immediately after RT. Upon recurrence, most patients were retreated with various chemotherapy regimens, including intrathecal chemotherapy in patients with leptomeningeal dissemination. The overall survival (OS) rate at 5 years was 73.3% (95% CI, 65.0-80.0%). The median OS for the whole group of patients was 112 months.
The data collected were mainly consistent with the literature. A limitation of this study was the large number of patients lost to follow-up and the lack of molecular data for most patients diagnosed until 2010. An important challenge for the future will be MB biologic characterization in adults, with the identification of specific genetic patterns. It will be important to have more national and international collaborations to provide evidence-based management strategies that attempt to obtain a standard of care.
髓母细胞瘤(MB)是儿童期最常见的原发性恶性颅内肿瘤,但在成人中非常罕见,因此,尚未确定最佳治疗方案。我们设计了一项多中心研究,以确定未来前瞻性研究的相关结局指标。
该项目涉及10个意大利中心。各中心共享的数据库包含流行病学、诊断(放射学和组织学/分子学)、治疗、复发信息和生存数据。
共有152例患者(102例男性和50例女性,中位年龄32岁)纳入研究。152例患者中有23例诊断为经典型髓母细胞瘤,52/152例为促纤维增生/广泛结节型,2/152例为大细胞间变型髓母细胞瘤,其余患者诊断未另行明确。几乎所有患者术后均接受了全脑全脊髓照射;85.5%的患者在放疗后立即进行了辅助化疗,主要是基于铂类和依托泊苷的化疗。复发时,大多数患者接受了各种化疗方案的再次治疗,包括脑膜播散患者的鞘内化疗。5年总生存率(OS)为73.3%(95%CI,65.0-80.0%)。全组患者的中位OS为112个月。
收集的数据主要与文献一致。本研究的一个局限性是大量患者失访,且大多数2010年前诊断的患者缺乏分子数据。未来的一个重要挑战将是对成人MB进行生物学特征分析,识别特定的基因模式。开展更多的国内和国际合作以提供基于证据的管理策略并试图获得标准治疗方案将非常重要。